Open One-arm Study to Investigate Safety and Efficacy of Intramuscular Injections of 1000 mg Testosterone Undecanoate (TU) in Hypogonadal Men at Variable Intervals During a 136-week to 192-week Treatment Including Pharmacokinetics
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Testosterone undecanoate (Primary)
- Indications Hypogonadism
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Bayer
- 25 Sep 2008 Trial identifier (91186) added as reported by CT.gov
- 25 Sep 2008 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
- 24 Oct 2006 Status change